Concepedia

AM Gonzalez-Angulo

AG

Statistics

Publications

6

Citations

127

H-Index

6

Active since

2009

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Novartis (Switzerland)

Sarah Cannon

AM Gonzalez-Angulo is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and molecular oncology.

Publications per year

2009–2013

6

Publications

6

BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Dejan Juric, Jordi Rodón, AM Gonzalez-Angulo et al. · Cancer Research · 2012 · 39 citations

, , +10

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with <i>PIK3CA</i> mutant advanced solid tumors: preliminary efficacy and safety in patients with <i>PIK3CA</i> mutant ER-positive (ER+) metastatic breast cancer (MBC)

Dejan Juric, Guillem Argilés, HA Burris et al. · Cancer Research · 2012 · 32 citations

, , +17

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.

Ronjay Rakkhit, Kristine Broglio, F Peintinger et al. · Cancer Research · 2009 · 20 citations

, , +11

Survival among women with triple receptor-negative breast cancer and brain metastases.

Shaheenah Dawood, K. Broglio, Francisco J. Esteva et al. · Cancer Research · 2009 · 13 citations

, , +11

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

Dejan Juric, AM Gonzalez-Angulo, HA Burris et al. · Cancer Research · 2013 · 12 citations

, , +13

1–5 of 6